Inflammatory response and its correction in forming a host response to exposure to adverse environmental factors
- 作者: Ponomarev D.1, Stepanov A.1, Ivchenko E.1,2, Seleznev A.1,3, Apchel V.2,4
-
隶属关系:
- State scientific-research test Institute of military medicine of the Ministry of Defense of the Russian Federation
- Military medical academy of S.M. Kirov
- North-western State Medical University named after I.I. Mechnikov
- A.I. Herzen Russian State Pedagogical University of the Ministry of Education and Science of the Russian Federation
- 期: 卷 24, 编号 1 (2022)
- 页面: 165-177
- 栏目: Review
- URL: https://journals.rcsi.science/1682-7392/article/view/83092
- DOI: https://doi.org/10.17816/brmma83092
- ID: 83092
如何引用文章
详细
This study systematically review knowledge about the mechanisms of formation of an inflammatory reaction under the influence of biological, physical, and chemical factors, their similarities and differences, and possible methods of pharmacological correction of pathological conditions associated with excessive activation. The effect of adverse environmental factors, such as biological, physical, and chemical factors, causes a systemic response, which is aimed at maintaining homeostasis and is caused, among other things, by a coordinated reaction of the immune system. Phlogogenic agents result in the activation and regulation of the inflammatory response, which is formed by cellular and humoral components of innate immunity. The activation of innate immunity is characterized by a rapid host response, which diminishes following the elimination of “foreign” invaders, endogenous killer cells, and neogenesis. Depending on the nature of the active factors (biopathogens, allergens, toxins, ionizing radiation, etc.), the mechanisms of immune response arousal have unique features mainly originating from the differences in the recognition of specific molecular patterns and “danger signals” by different receptors. However, inflammatory mediators and inflammatory response patterns at the systemic level are largely similar even under widely different triggers. Inflammation, having evolved as an adaptive reaction directed at the immune response, can lead to the development of chronic inflammation and autoimmune diseases due to a mismatch in mechanisms of its control. A “failure” in the regulation of the inflammatory process is the excessive activation of the immune system, which leads to the cytokine release syndrome (hypercytokinemia, or “cytokine storm”) and can cause self-damage (destruction) of tissues, multiple-organ failure, sepsis, and even death. Modern advances in the study of the pathogenetic bases of the inflammatory response are suggested, such as pharmacological correction using pattern recognition receptor antagonists, pro-inflammatory cytokine inhibitors, or blocking of key control genes or signaling pathways.
作者简介
Denis Ponomarev
State scientific-research test Institute of military medicine of the Ministry of Defense of the Russian Federation
编辑信件的主要联系方式.
Email: gniiivm_2@mil.ru
SPIN 代码: 3745-5748
candidate of biological sciences
俄罗斯联邦, Saint PetersburgAlexander Stepanov
State scientific-research test Institute of military medicine of the Ministry of Defense of the Russian Federation
Email: gniiivm_2@mil.ru
ORCID iD: 0000-0002-1917-2895
SPIN 代码: 7279-7055
doctor of medical sciences
俄罗斯联邦, Saint PetersburgEvgeny Ivchenko
State scientific-research test Institute of military medicine of the Ministry of Defense of the Russian Federation; Military medical academy of S.M. Kirov
Email: gniiivm_2@mil.ru
ORCID iD: 0000-0001-5582-1111
SPIN 代码: 5228-1527
doctor of medical sciences, associate professor
俄罗斯联邦, Saint Petersburg; Saint PetersburgAlexey Seleznev
State scientific-research test Institute of military medicine of the Ministry of Defense of the Russian Federation; North-western State Medical University named after I.I. Mechnikov
Email: gniiivm_2@mil.ru
ORCID iD: 0000-0003-4014-3973
SPIN 代码: 7853-3773
candidate of medical sciences, associate professor
俄罗斯联邦, Saint Petersburg; Saint PetersburgVasiliy Apchel
Military medical academy of S.M. Kirov; A.I. Herzen Russian State Pedagogical University of the Ministry of Education and Science of the Russian Federation
Email: gniiivm_2@mil.ru
ORCID iD: 0000-0001-7658-4856
SPIN 代码: 4978-0785
Scopus 作者 ID: 6507529350
Researcher ID: Е-8190-2019
doctor of medical sciences, professor
俄罗斯联邦, Saint Petersburg; Saint Petersburg参考
- Kim JH, Jenrow KA, Brown SL. Mechanisms of radiation-induced normal tissue toxicity and implications for future clinical trials. Radiat Oncol J. 2014;32(3):103–115. doi: 10.3857/roj.2014.32.3.103
- Chereshnev VA, Gusev EYu. Immunological and pathophysiological mechanisms of systemic inflammation. Medical Immunology (Russia). 2012;14(1-2):9–20. (In Russ.). doi: 10.15789/1563-0625-2012-1-2-9-20
- Chovatiya R, Medzhitov R. Stress, inflammation, and defense of homeostasis. Mol Cell. 2014;54(2):281–288. doi: 10.1016/j.molcel.2014.03.030
- Chen L, Deng H, Cui H, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018;9(6): 7204–7218. doi: 10.18632/oncotarget.23208
- Medzhitov R. Inflammation 2010: New adventures of an old flame. Cell. 2010;140(6):771–776. doi: 10.1016/j.cell.2010.03.006
- Litvitsky PF. Inflammation. Current Pediatrics. 2006;5(3):46–51. (In Russ.).
- Netea MG, Balkwill F, Chonchol M, et al. A guiding map for inflammation. Nat Immunol. 2017;18(8):826–831. doi: 10.1038/ni.3790
- Danyang L, Minghua W. Pattern recognition receptors in health and diseases. Signal Transduct Target Ther. 2021;6(1):291. doi: 10.1038/s41392-021-00687-0
- Relja B, Mörs K, Marzi I. Danger signals in trauma. Eur J Trauma Emerg Surg. 2018;44(3):301–316. doi: 10.1007/s00068-018-0962-3
- Relja B, Land WG. Damage-associated molecular patterns in trauma. Review Eur J Trauma Emerg Surg. 2020;46(4):751–775. doi: 10.1007/s00068-019-01235-w
- Takeuchi O, Akira Sh. Pattern Recognition Receptors and Inflammation. Cell. 2010;140(6):805–820. doi: 10.1016/j.cell.2010.01.022
- Barton GM. A calculated response: control of inflammation by the innate immune system. J Clin Invest. 2008;118(2):413–420. doi: 10.1172/JCI34431
- Garg AD, Galluzzi L, Apetoh L, et al. Molecular and translational classifications of DAMPs in immunogenic cell death. Front Immunol. 2015;6:588. doi: 10.3389/fimmu.2015.00588
- Tong A-J, Liu X, Thomas BJ, et al. A stringent systems approach uncovers gene-specific mechanisms regulating inflammation. Cell. 2016;165(1):165–179. doi: 10.1016/j.cell.2016.01.020
- Rivera A, Siracusa MC, Yap GS, Gause WC. Innate cell communication kick-starts pathogen-specific immunity. Nat Immunol. 2016;17(4):356–363. doi: 10.1038/ni.3375
- Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol. 2015;16(4):343–353. doi: 10.1038/ni.3123
- Almeida L, Lochner M, Berod L, Sparwasser T. Metabolic pathways in T cell activation and lineage differentiation. Semin Immunol. 2016;28(5):514–524. doi: 10.1016/j.smim.2016.10.009
- Buck MD, O’Sullivan D, Geltink RIK, et al. Mitochondrial dynamics controls T cell fate through metabolic programming. Cell. 2016;166(1):63–76. doi: 10.1016/j.cell.2016.05.035
- Goronzy JJ, Weyand CM. Successful and maladaptive T cell aging. Immunity. 2017;46(3):364–378. doi: 10.1016/j.immuni.2017.03.010
- Ageitos JM, Sánchez-Pérez A, Calo-Mata P, Villa TG. Antimicrobial peptides (AMPs): Ancient compounds that represent novel weapons in the fight against bacteria. Biochem Pharmacol. 2017;133: 117–138. doi: 10.1016/j.bcp.2016.09.018
- Chairatana Ph, Nolan EM. Defensins, lectins, mucins, and secretory immunoglobulin A: microbe-binding biomolecules that contribute to mucosal immunity in the human gut. Critical Rev Biochem Mol Biol. 2017;52(1):45–56. doi: 10.1080/10409238.2016.1243654
- Moschen AR, Adolph TE, Gerner RR, et al. Lipocalin-2: A master mediator of intestinal and metabolic inflammation. Trends Endocrinol Metabol. 2017;28(5):388–397. doi: 10.1016/j.tem.2017.01.003
- Hajishengallis G, Reis ES, Mastellos DC, et al. Novel mechanisms and functions of complement. Nat Immunol. 2017;18(12):1288–1298. doi: 10.1038/ni.3858
- Hau CS, Kanda N, Tada Y, et al. Lipocalin-2 exacerbates psoriasiform skin inflammation by augmenting T-helper 17 response. J Dermatol. 2016;43(7):785–794. doi: 10.1111/1346-8138.13227
- Bakunina LS, Litvinenko IV, Nakatis YaA, et al. Sepsis: pozhar i bunt na tonushchem v shtorm korable: monografiya. In 3th parts. Part I. Triggery vospaleniya. Retseptsiya triggerov vospaleniya i signal’naya transduktsiya. Pluzhnikov NN, Chepura SV, Khurtsilava OG, editors. Saint-Petersburg: Izd-vo SZGMU im. I.I. Mechnikova; 2018. 232 p. (In Russ.).
- Longo DL, Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020;383(23):2255–2273. doi: 10.1056/NEJMra2026131
- Tisoncik JR, Korth MJ, Simmons CP, et al. Into the Eye of the Cytokine Storm. Microbiol Mol Biol Rev. 2012;76(1):16–32. doi: 10.1128/MMBR.05015-11
- Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188–195. doi: 10.1182/blood-2014-05-552729
- Shimabukuro-Vornhagen A, Gödel Ph, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6(1):56. doi: 10.1186/s40425-018-0343-9
- Wong JP, Viswanathan S, Wang M. Current and future developments in the treatment of virus-induced hypercytokinemia. Future Med Chem. 2017;9(2):169–178. doi: 10.4155/fmc-2016-0181
- Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. J Infect. 2020;80(6):607–613. doi: 10.1016/j.jinf.2020.03.037
- Soy M, Keser G, Atagündüz P. Pathogenesis and treatment of cytokine storm in COVID-19. Turk J Biol. 2021;45(4):372–389. doi: 10.3906/biy-2105-37
- Kim JS, Lee JY, Yang JW, et al. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics. 2021;11(1): 316–329. doi: 10.7150/thno.49713
- Barker ChA, Kim SK, Budhu S, et al. Cytokine release syndrome after radiation therapy: case report and review of the literature. J Immunother Cancer. 2018;6(1):1. doi: 10.1186/s40425-017-0311-9
- Zhang Ch, Liang Zh, Ma Sh, et al. Radiotherapy and Cytokine Storm: Risk and Mechanism. Front Oncol. 2021;11:670464. doi: 10.3389/fonc.2021.670464
- Mukherjee D, Coates PhJ, Lorimore SA, Wright EG. Responses to ionizing radiation mediated by inflammatory mechanisms. J Pathol. 2014;232(3):289–299. doi: 10.1002/path.4299
- Schaue D, Micewicz ED, Ratikan JA, et al. Radiation and Inflammation. Semin Radiat Oncol. 2015;25(1):4–10. doi: 10.1016/j.semradonc.2014.07.007
- Yahyapour R, Amini P, Rezapour S, et al. Radiation-induced inflammation and autoimmune diseases. Mil Med Res. 2018;5:9. doi: 10.1186/s40779-018-0156-7
- Rios CI, Cassatt DR, Hollingsworth BA, et al. Commonalities between COVID-19 and radiation injury. Radiat Res. 2021;195(1): 1–24. doi: 10.1667/RADE-20-00188.1
- Gorbunov NV, Sharma P. Protracted oxidative alterations in the mechanism of hematopoietic acute radiation syndrome. Antioxidants (Basel). 2015;4(1):134–152. doi: 10.3390/antiox4010134
- Adjemian S, Oltean T, Martens S, et al. Ionizing radiation results in a mixture of cellular outcomes including mitotic catastrophe, senescence, methuosis, and iron-dependent cell death. Cell Death Dis. 2020;11(11):1003. doi: 10.1038/s41419-020-03209-y
- Chen Y, Li Y, Huang L, et al. Antioxidative stress: inhibiting reactive oxygen species production as a cause of radioresistance and chemoresistance. Oxid Med Cell Longev. 2021;8:6620306. doi: 10.1155/2021/6620306
- Jandhyala DM, Wong J, Mantis NJ, et al. A novel zak knockout mouse with a defective ribotoxic stress response. Toxins (Basel). 2016;8(9):259. doi: 10.3390/toxins8090259
- Wong J, Magun BE, Wood LJ. Lung inflammation caused by inhaled toxicants: a review. Int J Chron Obstruct Pulmon Dis. 2016;11(1):1391–1401. doi: 10.2147/COPD.S106009
- Lindauer ML, Wong J, Iwakura Y, Magun BE. Pulmonary inflammation triggered by ricin toxin requires macrophages and IL-1 signaling. J Immunol. 2009;183(2):1419–1426. doi: 10.4049/jimmunol.0901119
- Dong M, Yu H, Wang Y, et al. Critical role of toll-like receptor 4 (TLR4) in ricin toxin-induced inflammatory responses in macrophages. Toxicol Lett. 2020;321:54–60. doi: 10.1016/j.toxlet.2019.12.021
- Xu N, Yu K, Yu H, et al. Recombinant ricin toxin binding subunit B (RTB) stimulates production of TNF-α by mouse macrophages through activation of TLR4 signaling pathway. Front Pharmacol. 2020;11:526129. doi: 10.3389/fphar.2020.526129
- Chikuma Sh. CTLA-4, an essential immune-checkpoint for Tcell activation. Curr Top Microbiol Immunol. 2017;410:99–126. doi: 10.1007/82_2017_61
- Dimeloe S, Mehling M, Frick C, et al. The immune-metabolic basis of effector memory CD4+ Tcell function under hypoxic conditions. J Immunol. 2016;196(1):106–114. doi: 10.4049/jimmunol.1501766
- Liu Q, Zhou Y, Yang Zh. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol. 2016;13(1):3–10. doi: 10.1038/cmi.2015.74
- Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393. doi: 10.1016/j.clim.2020.108393
- Cavalli G, Dinarello ChA. Anakinra therapy for non-cancer inflammatory diseases. Front Pharmacol. 2018;9:1157. doi: 10.3389/fphar.2018.01157
- Dinarello ChA. Treatment of inflammatory diseases with IL-1 blockade. Curr Otorhinolaryngol Rep. 2018;6(1):1–14. doi: 10.1007/s40136-018-0181-9
- Christersdottir T, Pirault J, Gisterå A, et al. Prevention of radiotherapy-induced arterial inflammation by interleukin-1 blockade. Eur Heart J. 2019;40(30):2495–2503. doi: 10.1093/eurheartj/ehz206
- Gao W, Xiong Y, Li Q, Yang H. Inhibition of Toll-like receptor signaling as a promising therapy for inflammatory diseases: A journey from molecular to nano therapeutics. Front Physiol. 2017;8:508. doi: 10.3389/fphys.2017.00508
- Obinata H, Hla T. Sphingosine 1-phosphate and inflammation. Int Immunol. 2019;31(9):617–625. doi: 10.1093/intimm/dxz037
- Marsolais D, Hahm B, Kevin B, et al. A critical role for the sphingosine analog AAL-R in dampening the cytokine response during influenza virus infection. Proc Natl Acad Sci USA. 2009;106(5): 1560–1565. doi: 10.1073/pnas.0812689106
- Walsh KB, Teijaro JR, Wilker PR, et al. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc Natl Acad Sci USA. 2011;108(29):12018–12023. doi: 10.1073/pnas.1107024108
- Teijaro JR, Walsh KB, Rice S, et al. Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection. Proc Natl Acad Sci USA. 2014;111(10):3799–3804. doi: 10.1073/pnas.1400593111
- Jacobson JR. Sphingolipids as a novel therapeutic target in radiation-induced lung injury. Cell Biochem Biophys. 2021;79(3): 509–516. doi: 10.1007/s12013-021-01022-8
- Naz1 F, Arish M. Battling COVID-19 Pandemic: Sphingosine-1-Phosphate Analogs as an Adjunctive Therapy? Front Immunol. 2020;11:1102. doi: 10.3389/fimmu.2020.01102
- Tasat DR, Yakisich JS. Rationale for the use of sphingosine analogues in COVID-19 patients. Clin Med (Lond). 2021;21(1): e84–e87. doi: 10.7861/clinmed.2020-0309